ROC offers a variety of technical services including ultrasound examinations, fetal monitoring, amniocentesis, chorionic villus sampling (CVS), fetal blood sampling, first and second trimester screening and the cell free fetal DNA non-invasive prenatal testing (NIPT).
Our state-of-the-art ultrasound equipment and experienced staff allow more detailed ultrasound experiences.
Non-invasive fetal monitoring is performed as part of a comprehensive biophysical profile assessment. Fetal monitoring is indicated in the third trimester to assess fetal well-being in women with high-risk factors.
CVS and amniocentesis are diagnostic tests and enable the unborn baby's chromosomes to be studied to detect Down syndrome or other chromosomal abnormalities. The chromosomal analysis has greater than 99% accuracy. Other genetic testing can be performed by CVS or amniocentesis as indicated. CVS is performed between 10 and 12 weeks gestation. Amniocentesis is typically performed between 15 and 18 weeks gestation but can be performed later. Fetal blood sampling, or cordocentesis, is only used for a limited number of high risk situations such as the need for a fetal blood transfusion. All diagnostic tests have a small risk of complications.
Unlike a diagnostic test, a screening test does not give a definite result. However, it can indicate if there is an increased or decreased risk for a particular problem in the developing baby. Screening has the advantage that there is no risk to the pregnancy. All screening has the chance of false positives or false negatives.
First trimester screening is performed between 11 and 13 weeks gestation. This screening involves a specialized ultrasound and a blood test. Ultrasound technologists must have special certification to perform first trimester screening. The screen is used to detect an increased risk for Down syndrome, Trisomy 13 and Trisomy 18. These three conditions are chromosomal abnormalities that can result in varying degrees of intellectual disability and birth defects for a developing baby.
With ultrasound, a special measurement, called nuchal translucency, is taken. This is a measurement at the back of the baby's neck. With ultrasound the sonographer also attempts to see the nasal bone. Blood work is also done. Two chemicals, free beta hCG and PAPP-A are measured in the woman's blood. The ultrasound measurements, blood work and the woman's age are combined to create her personalized risk to have a baby with Down syndrome, Trisomy 18 and Trisomy 13. The result of the screening test is usually available within one week.
First trimester screening can only give an estimate of risk such as 1 in 100. First trimester screening has a detection rate of 90% or greater. This means that not all babies with these conditions will test positive on the screen. Thus a normal result does not guarantee that the baby does not have one of the three conditions. The only way to know for sure if a baby has one of these chromosome abnormalities is to have a diagnostic test such as CVS or amniocentesis.
Second trimester screening, such as a quad screen, is a blood test that is typically performed between 15 and 20 weeks of gestation. This screening also is used to detect an increased risk for Down syndrome and Trisomy 18. However, the detection rate is not as high as with first trimester screening. Second trimester screening can also detect an increased risk for open spine defects such as spina bifida.
The newest screening available is called non-invasive prenatal testing or NIPT. NIPT is offered through four different laboratories in the United States and goes by the names MaterniT21Plus, Verifi, Harmony and Panorama. NIPT is performed by analyzing circulating cell free fetal DNA in the mother’s blood.
NIPT has the highest detection rate of any screen currently available, and is more comprehensive. In addition to screening for Down syndrome, Trisomy 13 and Trisomy 18, NIPT will also detect an increased risk for X and Y chromosomal abnormalities. NIPT is a blood test and can be performed from 10 weeks gestation on. Results are usually available within 10 days.
Currently NIPT is only recommended for women in the following categories:
While NIPT has a high detection rate for the major chromosomal abnormalities, it is not diagnostic. False positives do occur. CVS or amniocentesis would be necessary to rule out or confirm these and other chromosomal abnormalities.
Screening can provide a woman with reassurance that her pregnancy is not at increased risk for certain abnormalities. If the pregnancy is at increased risk, the patient has the option of a diagnostic test to find out if the baby does have the condition. Knowing the baby has a chromosomal abnormality allows better management of the pregnancy between the patient and her doctor, facilitating a healthier outcome.